An observational study in Peritoneal (Metastatic) Cancer, Colorectal Cancer and Colorectal (Colon or Rectal) Cancer, sponsored by Jules Bordet Institute. Recruiting at 2 sites in Belgium. Open to participants aged Up to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Jules Bordet Institute · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 262 studies in Neoplasm Metastasis with a site in Belgium — 39 open to participants now, 77 under way, 31 of them phase 3. Neoplasm Metastasis · Belgium.
Among the 262 studies in Neoplasm Metastasis with a site in Belgium, this one is the 13th largest by planned enrollment of the 14 observational ones that give a count, is one of 4 that started in 2026, is one of 14 observational ones, reaches primary completion later than 65 of the 76 other live ones, and was the 261st registered.
4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.
Browse Neoplasm Metastasis studies →39 of the 262 studies in Neoplasm Metastasis with a site in Belgium are open now. Recruiting first, the newest first:
University Hospital, Ghent · Sites in Belgium
Ages 18+
Amgen · Sites in Belgium, United States, Australia and 7 more countries
Ages 18–99
Eikon Therapeutics · Sites in Belgium, United States, Australia and 12 more countries
Ages 18+
Eli Lilly and Company · Sites in Belgium, United States, Argentina and 16 more countries
Ages 18+
Pfizer · Sites in Belgium, United States, Argentina and 17 more countries
Ages 18+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.
This study: Up to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
262 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 69 · Phase 2 105 · Phase 3 88 · Phase 4 1
First in 1992; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 137 across 561 observational studies indexed under Neoplasm Metastasis.
Median enrollment 206 across the 242 interventional studies, 62 across the 14 observational. Of the 168 that completed or were terminated, 89 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
194 of 262 have an industry lead sponsor. The 10 most frequent:
Jules Bordet Institute is the lead sponsor of 106 studies on the registry; 27 are open to participants now.
Jules Bordet Institute has 8 studies filed under Neoplasm Metastasis — fewer than ten, so there is no comparison to draw.
20 of the studies in Neoplasm Metastasis with a site in Belgium that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05352178Phase 3Universitaire Ziekenhuizen KU LeuvenMetastasis-directed Therapy for Oligorecurrent Prostate Cancer | 2027-04-25 |
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
| NCT06064877Phase 3AVEO Pharmaceuticals, Inc.A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma | 2027-08 |
| NCT07044336Phase 3AstraZenecaPuxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | 2027-10-15 |
| NCT06119581Phase 3Eli Lilly and CompanyA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | 2027-11 |
Add all 20 to your calendar (.ics) → With an account.
Among the 262 studies in Neoplasm Metastasis with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
his prospective, single-center observational pilot study evaluates whether peritoneal histopathological growth patterns can be assessed on limited excisional biopsies obtained during staging laparoscopy in adults with suspected or confirmed colorectal peritoneal metastases. The study primarily evaluates agreement between the dominant histopathological growth pattern identified on laparoscopic biopsy and that identified on subsequent operative specimens.
One to three peritoneal deposits will be sampled during staging laparoscopy. When surgery proceeds, up to three peritoneal deposits will be collected from the operative specimen, preferably from corresponding Peritoneal Cancer Index regions. Two pathologists, blinded to clinical information, specimen timing, and each other's assessments, will independently estimate the proportions of pushing and infiltrating growth patterns.
Histopathological growth pattern findings will not be used to guide clinical management. Biopsy evaluability, interobserver reproducibility, interlesional heterogeneity, and exploratory associations with clinical and surgical characteristics will also be assessed.
Peritoneal histopathological growth patterns (HGPs) describe the morphological interface between metastatic tumor deposits and the surrounding peritoneal tissue and may provide biological information that is not captured by conventional clinical or pathological variables. This prospective, single-center observational pilot study aims to determine whether peritoneal HGPs can be reliably assessed on limited biopsies obtained during staging laparoscopy and whether the dominant HGP identified on these biopsies agrees with that identified on subsequent cytoreductive surgery (CRS) specimens. Thirty adult patients with colorectal peritoneal metastases who are scheduled to undergo both staging laparoscopy and cytoreductive surgery, with or without hyperthermic intraperitoneal chemotherapy, will be prospectively enrolled.
During staging laparoscopy, one to three peritoneal deposits will be sampled using cold scissors. CRS will subsequently be performed within eight weeks, without interval systemic anticancer treatment. During CRS up to three additional peritoneal deposits will be collected, preferably from the same PCI regions or anatomical compartments as the laparoscopic samples. Two pathologists, blinded to clinical information, specimen timing, and each other's assessments, will independently estimate the proportions of pushing and infiltrating HGP at the tumor-peritoneum interface according to a prespecified histopathological standard operating procedure. The primary outcome will be patient-level agreement in dominant HGP classification between staging-laparoscopy biopsies and cytoreductive surgery specimens. Secondary outcomes will include biopsy evaluability, interobserver agreement, agreement in continuous HGP proportions, interlesional heterogeneity, and exploratory associations between HGP and primary-tumor characteristics, PCI, and completeness of cytoreduction. Overall survival and disease-free survival will be explored descriptively; however, the study is not powered to establish the prognostic value or clinical utility of HGP. HGP assessments will not be used to guide treatment decisions, which will remain based on standard multidisciplinary clinical evaluation.
The study population consists of adult patients with histologically confirmed colorectal cancer and suspected or confirmed peritoneal metastases who undergo surgical evaluation or treatment (staging laparoscopy and/or cytoreductive surgery ± HIPEC) as part of routine clinical care at participating centers. Peritoneal metastasis tissue samples obtained during these procedures are used for histopathological analysis to evaluate histological growth patterns and their association with clinicopathological characteristics and clinical outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients with histologically confirmed colorectal cancer and suspected or confirmed peritoneal metastases undergoing standard-of-care surgical evaluation or treatment (staging laparoscopy and/or cytoreductive surgery ± HIPEC). Peritoneal metastasis tissue samples obtained during routine clinical care are analyzed histologically to assess histological growth patterns and their association with clinical and pathological outcomes. No experimental intervention is performed as part of the study.
Concordance of peritoneal histopathological growth pattern classification between staging-laparoscopy biopsies and subsequent cytoreductive surgery specimens.
Histological characterization of colorectal peritoneal metastases according to predefined histological growth pattern criteria (e.g., pushing, infiltrative/replacement, or mixed patterns) on hematoxylin and eosin (H\&E)-stained tissue sections obtained from peritoneal biopsies or surgical specimens. The proportion of each HGP type will be determined.
Time frame: At time of histopathological analysis of surgical or laparoscopic biopsy specimens (baseline, during initial surgical evaluation).
Association between histological growth patterns and peritoneal disease burden
Assessment of the relationship between histological growth pattern and extent of peritoneal disease as measured by the Peritoneal Cancer Index (PCI).
Time frame: At time of surgery or staging laparoscopy.
Association between histological growth patterns and histopathological tumor characteristics
Evaluation of associations between HGP and tumor-related characteristics including differentiation grade, molecular markers, and other pathological features of colorectal cancer.
Time frame: At time of histopathological analysis.
Association between histological growth patterns and survival outcomes
Evaluation of the relationship between HGP and clinical outcomes including overall survival and progression-free survival.
Time frame: Up to 2 years after surgery or diagnosis of peritoneal metastases.
Plan to share: No — Individual participant data will not be shared publicly due to patient confidentiality considerations and institutional data protection policies in accordance with applicable regulations (including GDPR).
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Dec 2028, 33 months after the start.
Of 211 non-industry observational studies under Neoplasm Metastasis, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 172. This study's planned 33 months is below that.
Counting every sponsor, half of 242 studies reached it within 66 months; a quarter within 35 and three quarters within 172.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.